BGNE:NGS-BeiGene Ltd. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 166.58

Change

+9.60 (+6.12)%

Market Cap

USD 1.04B

Volume

0.29M

Analyst Target

USD 237.90
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product include BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.27B
MRNA Moderna Inc

N/A

USD 28.23B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
UTHR United Therapeutics Corporatio..

N/A

USD 15.72B
INSM Insmed Inc

N/A

USD 12.93B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.85B

ETFs Containing BGNE

MSGR 6.80 % 0.00 %

N/A

N/A
S6EW:SW Ossiam STOXX® Europe 600.. 6.12 % 0.00 %

N/A

USD 0.11B
ELOVD:SW UBS(Lux)Fund Solutions .. 1.98 % 0.00 %

N/A

N/A
EDGE:CA Evolve Innovation Index F.. 1.45 % 0.60 %

N/A

CAD 0.04B
EDGE-U:CA Evolve Innovation Index F.. 1.45 % 0.00 %

N/A

N/A
ELOW:SW SPDR® EURO STOXX Low Vol.. 1.17 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 1.02 % 0.00 %

N/A

CAD 0.68B
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.45B
PHR:CA 0.00 % 0.78 %

N/A

N/A
KURE KraneShares MSCI All Chin.. 0.00 % 0.79 %

N/A

USD 0.04B
KMED 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
XRE:CA iShares S&P/TSX Capped RE.. 0.00 % 0.61 %

N/A

CAD 1.25B
FLHK Franklin FTSE Hong Kong E.. 0.00 % 0.09 %

N/A

USD 0.01B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

N/A
LOWE:LSE 0.00 % 0.00 %

N/A

N/A
XMLA:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

N/A

N/A
XMLD:LSE Xtrackers MSCI EM Latin A.. 0.00 % 0.00 %

N/A

N/A
XS3R:LSE Xtrackers MSCI Europe Con.. 0.00 % 0.00 %

N/A

USD 0.06B
XSNR:LSE Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.03B
XDGM:LSE 0.00 % 0.00 %

N/A

N/A
EMMV:PA 0.00 % 0.00 %

N/A

N/A
S6EW:PA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.12B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

N/A
EUN0:F iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

N/A

N/A
UIMY:F UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

N/A

USD 0.05B
DXSK:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.07B
EUN0:XETRA iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

USD 0.79B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

N/A

USD 0.16B
OSX9:XETRA 0.00 % 0.00 %

N/A

N/A
UIMY:XETRA 0.00 % 0.00 %

N/A

N/A
TGRE:CA TD Active Global Real Est.. 0.00 % 0.00 %

N/A

CAD 0.07B
TPIF Timothy Plan Internationa.. 0.00 % 0.00 %

N/A

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 7.81M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 7.81M
LCDE:XETRA BNP Paribas Easy - Low Ca.. 0.00 % 0.00 %

N/A

USD 0.02B
MVEU:SW iShares Edge MSCI Europe .. 0.00 % 0.00 %

N/A

USD 0.76B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.64% 52% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.64% 52% F 36% F
Trailing 12 Months  
Capital Gain -12.22% 56% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.22% 56% F 39% F
Trailing 5 Years  
Capital Gain 20.89% 76% C+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.89% 76% C+ 55% F
Average Annual (5 Year Horizon)  
Capital Gain 15.01% 72% C 75% C
Dividend Return 15.01% 72% C 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.50% 50% F 29% F
Risk Adjusted Return 26.57% 82% B 61% D-
Market Capitalization 1.04B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 4.17 35% 26%
Price / Cash Flow Ratio -14.63 85% 86%
Price/Free Cash Flow Ratio -11.91 89% 86%
Management Effectiveness  
Return on Equity -20.87% 88% 43%
Return on Invested Capital -27.04% 76% 30%
Return on Assets -11.81% 86% 31%
Debt to Equity Ratio 5.59% 62% 77%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.